Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT)

$11.68 -0.50 (-4.11 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$11.68
Today's Range$11.58 - $12.35
52-Week Range$8.80 - $16.86
Volume52,082 shs
Average Volume175,283 shs
Market Capitalization$168.62 million
P/E Ratio-116.80
Dividend YieldN/A
Beta0.73

About Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics logoSummit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939

Debt

Debt-to-Equity RatioN/A
Current Ratio4.06%
Quick Ratio4.06%

Price-To-Earnings

Trailing P/E Ratio-116.8
Forward P/E Ratio-25.39
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.90 million
Price / Sales55.74
Cash FlowN/A
Price / CashN/A
Book Value($0.38) per share
Price / Book-30.74

Profitability

Trailing EPS($0.10)
Net Income$-28,590,000.00
Net Margins-0.95%
Return on Equity-10.90%
Return on Assets-0.57%

Miscellaneous

Employees40
Outstanding Shares13,840,000

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (NASDAQ:SMMT) announced its earnings results on Wednesday, December, 6th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.73) by $0.53. The firm earned $2.29 million during the quarter, compared to analyst estimates of $2.32 million. Summit Therapeutics had a negative net margin of 0.95% and a negative return on equity of 10.90%. View Summit Therapeutics' Earnings History.

When will Summit Therapeutics make its next earnings announcement?

Summit Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 4th 2018. View Earnings Estimates for Summit Therapeutics.

Where is Summit Therapeutics' stock going? Where will Summit Therapeutics' stock price be in 2018?

5 Wall Street analysts have issued 12-month price targets for Summit Therapeutics' shares. Their forecasts range from $16.00 to $33.00. On average, they expect Summit Therapeutics' share price to reach $26.20 in the next year. View Analyst Ratings for Summit Therapeutics.

Who are some of Summit Therapeutics' key competitors?

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the folowing people:

  • Glyn Edwards, Chief Executive Officer, Executive Director (Age 59)
  • Erik Ostrowski, Chief Financial Officer (Age 42)
  • David Roblin, Chief Operating Officer, President - Research and Development
  • Ralf H. Rosskamp M.D., Chief Medical Officer (Age 63)
  • Frank Murdoch Armstrong, Non-Executive Chairman of the Board (Age 60)
  • Valerie L. Andrews, Non-Executive Director (Age 55)
  • Stephen J. Davies, Non-Executive Director (Age 64)
  • Barry J. Price Ph.D., Non-Executive Director (Age 71)
  • David Wurzer CPA, Non-Executive Director

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who owns Summit Therapeutics stock?

Summit Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (1.04%), Renaissance Technologies LLC (0.84%) and Millennium Management LLC (0.72%). View Institutional Ownership Trends for Summit Therapeutics.

Who bought Summit Therapeutics stock? Who is buying Summit Therapeutics stock?

Summit Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Millennium Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Summit Therapeutics.

How do I buy Summit Therapeutics stock?

Shares of Summit Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Summit Therapeutics' stock price today?

One share of Summit Therapeutics stock can currently be purchased for approximately $11.68.

How big of a company is Summit Therapeutics?

Summit Therapeutics has a market capitalization of $168.62 million and generates $2.90 million in revenue each year. The company earns $-28,590,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. Summit Therapeutics employs 40 workers across the globe.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX14 4RY. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]


MarketBeat Community Rating for Summit Therapeutics (SMMT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Summit Therapeutics (NASDAQ:SMMT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.20$23.00$26.00$27.40
Price Target Upside: 142.59% upside106.46% upside114.34% upside138.47% upside

Summit Therapeutics (NASDAQ:SMMT) Consensus Price Target History

Price Target History for Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ:SMMT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018BTIG ResearchInitiated CoverageBuy -> Buy$33.00HighView Rating Details
1/26/2018OppenheimerBoost Price TargetOutperform -> Outperform$24.00 -> $30.00HighView Rating Details
1/25/2018HC WainwrightReiterated RatingBuy$16.00HighView Rating Details
1/4/2018SunTrust BanksInitiated CoverageBuy -> Buy$24.00LowView Rating Details
10/16/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$26.00 -> $29.00N/AView Rating Details
10/4/2016Needham & Company LLCBoost Price TargetBuy$22.00 -> $30.00N/AView Rating Details
6/21/2016Janney Montgomery ScottInitiated CoverageBuyN/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Summit Therapeutics (NASDAQ:SMMT) Earnings History and Estimates Chart

Earnings by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ SMMT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/4/2018        
12/6/2017Q3 2018($0.73)($0.20)$2.32 million$2.29 millionViewN/AView Earnings Details
8/31/20177/31/2017$1.38$1.10$31.37 million$25.01 millionViewN/AView Earnings Details
6/14/2017Q1 2018($0.65)($0.50)$2.29 million$2.24 millionViewN/AView Earnings Details
3/29/2017Q4 2017($0.71)($0.50)$0.07 million$2.18 millionViewN/AView Earnings Details
12/15/2016Q3 2017($0.80)($0.45)$0.15 million$0.70 millionViewN/AView Earnings Details
9/8/2016Q2 2017($0.69)($0.65)$0.34 million$0.02 millionViewN/AView Earnings Details
6/2/2016Q1 2017($0.64)($0.65)$0.36 million$0.09 millionViewN/AView Earnings Details
5/10/2016Q4 2016($0.55)ViewN/AView Earnings Details
12/17/2015Q3 2016($0.08)($0.60)$0.39 million$0.58 millionViewN/AView Earnings Details
8/27/2015Q215($0.06)($0.55)$0.39 million$0.67 millionViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)$0.39 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Summit Therapeutics (NASDAQ:SMMT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.11)
2019 EPS Consensus Estimate: ($3.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.65)($0.65)($0.65)
Q2 20181$1.15$1.15$1.15
Q3 20181($0.73)($0.73)($0.73)
Q4 20182($0.90)($0.86)($0.88)
Q1 20191($0.75)($0.75)($0.75)
Q2 20191($0.85)($0.85)($0.85)
Q3 20191($1.05)($1.05)($1.05)
Q4 20191($1.25)($1.25)($1.25)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics (NASDAQ:SMMT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics (NASDAQ SMMT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Summit Therapeutics (NASDAQ SMMT) News Headlines

Source:
DateHeadline
ValuEngine Downgrades Summit Therapeutics (SMMT) to SellValuEngine Downgrades Summit Therapeutics (SMMT) to Sell
www.americanbankingnews.com - February 9 at 11:12 PM
Zacks: Analysts Expect Summit Therapeutics PLC (SMMT) to Post -$0.77 Earnings Per ShareZacks: Analysts Expect Summit Therapeutics PLC (SMMT) to Post -$0.77 Earnings Per Share
www.americanbankingnews.com - February 5 at 3:12 AM
ValuEngine Upgrades Summit Therapeutics (SMMT) to "Hold"ValuEngine Upgrades Summit Therapeutics (SMMT) to "Hold"
www.americanbankingnews.com - February 4 at 1:16 PM
Summit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by BrokeragesSummit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 29 at 3:16 AM
Summit Therapeutic (SMMT) Says Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data from PhaseOut DMD Clinical TrialSummit Therapeutic (SMMT) Says Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data from PhaseOut DMD Clinical Trial
www.streetinsider.com - January 27 at 9:16 AM
Summit Therapeutics (SMMT) Price Target Increased to $30.00 by Analysts at OppenheimerSummit Therapeutics (SMMT) Price Target Increased to $30.00 by Analysts at Oppenheimer
www.americanbankingnews.com - January 26 at 3:48 PM
Summit Therapeutics (SMMT) Rating Reiterated by HC WainwrightSummit Therapeutics (SMMT) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - January 25 at 12:50 PM
Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMDSummit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD
uk.finance.yahoo.com - January 25 at 8:57 AM
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
finance.yahoo.com - January 25 at 8:57 AM
Summit Therapeutics PLC (SMMT) Expected to Announce Quarterly Sales of $4.67 MillionSummit Therapeutics PLC (SMMT) Expected to Announce Quarterly Sales of $4.67 Million
www.americanbankingnews.com - January 21 at 10:56 AM
Summit Therapeutics (SMMT) Upgraded by Zacks Investment Research to "Strong-Buy"Summit Therapeutics (SMMT) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - January 12 at 8:50 AM
Summit Therapeutics to Present at the Biotech Showcase - GlobeNewswire (press release)Summit Therapeutics to Present at the Biotech Showcase - GlobeNewswire (press release)
globenewswire.com - January 9 at 11:09 AM
SunTrust Banks Comments on Summit Therapeutics PLCs FY2018 Earnings (SMMT)SunTrust Banks Comments on Summit Therapeutics PLC's FY2018 Earnings (SMMT)
www.americanbankingnews.com - January 8 at 9:38 AM
Summit Therapeutics (SMMT) Upgraded to Hold by Zacks Investment ResearchSummit Therapeutics (SMMT) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - January 7 at 8:37 AM
SunTrust Robinson Humphrey Starts Summit Therapeutics plc ... - StreetInsider.comSunTrust Robinson Humphrey Starts Summit Therapeutics plc ... - StreetInsider.com
www.streetinsider.com - January 4 at 3:40 PM
Summit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Hold" from AnalystsSummit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 4 at 10:26 AM
SunTrust Banks Initiates Coverage on Summit Therapeutics (SMMT)SunTrust Banks Initiates Coverage on Summit Therapeutics (SMMT)
www.americanbankingnews.com - January 4 at 8:12 AM
Zacks: Brokerages Expect Summit Therapeutics PLC (SMMT) to Post -$0.93 EPSZacks: Brokerages Expect Summit Therapeutics PLC (SMMT) to Post -$0.93 EPS
www.americanbankingnews.com - January 2 at 12:18 PM
Summit Therapeutics (SMMT) PT Set at $16.00 by HC WainwrightSummit Therapeutics (SMMT) PT Set at $16.00 by HC Wainwright
www.americanbankingnews.com - December 28 at 10:14 PM
Summit Therapeutics (SMMT) Lowered to "Sell" at Zacks Investment ResearchSummit Therapeutics (SMMT) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - December 28 at 9:02 AM
Its Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed ... - NasdaqIt's Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed ... - Nasdaq
www.nasdaq.com - December 24 at 4:25 PM
Summit Ther Share ChatSummit Ther Share Chat
www.lse.co.uk - December 24 at 2:21 AM
Summit Obtains Innovative Antibiotic Discovery and Development ... - GlobeNewswire (press release)Summit Obtains Innovative Antibiotic Discovery and Development ... - GlobeNewswire (press release)
globenewswire.com - December 23 at 9:18 PM
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva LtdSummit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
finance.yahoo.com - December 23 at 4:17 PM
Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole - GlobeNewswire (press release)Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole - GlobeNewswire (press release)
globenewswire.com - December 22 at 9:44 PM
$4.85 Million in Sales Expected for Summit Therapeutics PLC (SMMT) This Quarter$4.85 Million in Sales Expected for Summit Therapeutics PLC (SMMT) This Quarter
www.americanbankingnews.com - December 18 at 8:50 AM
Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017Summit Therapeutics Plc :SMMT-US: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017
finance.yahoo.com - December 11 at 12:03 PM
Summit Therapeutics (SMMT) "Buy" Rating Reiterated at HC WainwrightSummit Therapeutics' (SMMT) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - December 7 at 3:39 PM
Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational ProgressSummit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress
finance.yahoo.com - December 6 at 8:48 AM
Summit Therapeutics (SMMT) Set to Announce Earnings on WednesdaySummit Therapeutics (SMMT) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - December 5 at 1:30 PM
Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017
finance.yahoo.com - December 4 at 11:52 AM
Summit Therapeutics (SMMT) Now Covered by HC WainwrightSummit Therapeutics (SMMT) Now Covered by HC Wainwright
www.americanbankingnews.com - December 1 at 7:49 AM
 Brokerages Expect Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $2.32 Million Brokerages Expect Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $2.32 Million
www.americanbankingnews.com - November 30 at 11:16 AM
-$0.73 EPS Expected for Summit Therapeutics PLC (SMMT) This Quarter-$0.73 EPS Expected for Summit Therapeutics PLC (SMMT) This Quarter
www.americanbankingnews.com - November 28 at 11:14 AM
Summit Therapeutics PLC (SMMT) Upgraded to "Hold" by Zacks Investment ResearchSummit Therapeutics PLC (SMMT) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - November 25 at 11:28 AM
Summit Therapeutics to Participate in Upcoming Investor ConferencesSummit Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 22 at 8:08 AM
Summit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In PhaseOut DMD Clinical TrialSummit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In PhaseOut DMD Clinical Trial
www.thestreet.com - November 20 at 8:25 PM
Summit Therapeutics Closes in on DMD Results - 24/7 Wall St.Summit Therapeutics Closes in on DMD Results - 24/7 Wall St.
247wallst.com - November 20 at 3:22 PM
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial - GlobeNewswire (press release)Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial - GlobeNewswire (press release)
globenewswire.com - November 20 at 10:02 AM
Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
finance.yahoo.com - November 20 at 10:02 AM
$2.32 Million in Sales Expected for Summit Therapeutics PLC (SMMT) This Quarter$2.32 Million in Sales Expected for Summit Therapeutics PLC (SMMT) This Quarter
www.americanbankingnews.com - November 11 at 8:10 AM
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne - GlobeNewswire (press release)Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne - GlobeNewswire (press release)
www.globenewswire.com - November 9 at 1:35 PM
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ConferenceSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
finance.yahoo.com - November 9 at 1:35 PM
Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive DirectorsGrant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive Directors
finance.yahoo.com - October 25 at 10:50 AM
Summit Therapeutics PLC (SMMT) Expected to Post Quarterly Sales of $2.32 MillionSummit Therapeutics PLC (SMMT) Expected to Post Quarterly Sales of $2.32 Million
www.americanbankingnews.com - October 23 at 1:24 PM
Summit Therapeutics PLC (SMMT) Expected to Announce Earnings of -$0.63 Per ShareSummit Therapeutics PLC (SMMT) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - October 21 at 2:20 AM
Summit Therapeutics PLC (SMMT) Receives "Buy" Rating from Canaccord GenuitySummit Therapeutics PLC (SMMT) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - October 16 at 9:58 PM
Summit Therapeutics PLC (SMMT) Receives Buy Rating from Oppenheimer Holdings, Inc.Summit Therapeutics PLC (SMMT) Receives Buy Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 16 at 4:46 PM
Summit Therapeutics PLC (SMMT) Downgraded by Zacks Investment ResearchSummit Therapeutics PLC (SMMT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 12:16 PM
ValuEngine Lowers Summit Therapeutics PLC (SMMT) to SellValuEngine Lowers Summit Therapeutics PLC (SMMT) to Sell
www.americanbankingnews.com - October 8 at 3:32 PM

SEC Filings

Summit Therapeutics (NASDAQ:SMMT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Summit Therapeutics (NASDAQ:SMMT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Summit Therapeutics (NASDAQ SMMT) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.